Jove
Visualize
Contact Us

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Melanoma-specific Survival Of Patients With Uveal Melanoma And Liver Metastases Diagnosed Between 2005 And 2021.
  1. Home
  3. Melanoma-specific Survival Of Patients With Uveal Melanoma And Liver Metastases Diagnosed Between 2005 And 2021.

Related Experiment Video

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.4K

Melanoma-specific survival of patients with uveal melanoma and liver metastases diagnosed between 2005 and 2021.

Lisa Wiens1, Gerd Grözinger2, Helmut Dittmann3

  • 1Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tübingen, Liebermeisterstr. 25, Tübingen 72076, Germany.

Therapeutic Advances in Medical Oncology
|August 26, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Improved survival for uveal melanoma patients with liver metastases is linked to liver-directed therapy. This approach offers better melanoma-specific survival (MSS) compared to systemic therapy, especially in recent treatment groups.

Keywords:
chemotherapyimmunotherapymelanomametastasisuvea melanoma

More Related Videos

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
05:46

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography

Published on: December 2, 2022

1.7K
Generation of a Liver Orthotopic Human Uveal Melanoma Xenograft Platform in Immunodeficient Mice
04:02

Generation of a Liver Orthotopic Human Uveal Melanoma Xenograft Platform in Immunodeficient Mice

Published on: November 6, 2019

8.6K

Related Experiment Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.4K
Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
05:46

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography

Published on: December 2, 2022

1.7K
Generation of a Liver Orthotopic Human Uveal Melanoma Xenograft Platform in Immunodeficient Mice
04:02

Generation of a Liver Orthotopic Human Uveal Melanoma Xenograft Platform in Immunodeficient Mice

Published on: November 6, 2019

8.6K

Area of Science:

  • Ophthalmology
  • Medical Oncology
  • Dermatology

Background:

  • Uveal melanoma is the most common primary intraocular malignancy in adults.
  • Metastatic uveal melanoma frequently involves the liver, significantly impacting patient prognosis.
  • Liver metastases are associated with poorer survival outcomes than extrahepatic disease.

Purpose of the Study:

  • To evaluate the impact of treatment strategies on survival outcomes in patients with metastatic uveal melanoma.
  • To compare the efficacy of liver-directed therapy versus systemic therapy as first-line treatment for liver metastases.
  • To analyze survival trends in metastatic uveal melanoma over time.

Main Methods:

  • Retrospective analysis of 167 patients diagnosed with metastatic uveal melanoma between 2005 and 2021.
  • Patients were stratified into two groups based on the timing of metastasis diagnosis (2005-2015 vs. 2016-2021).
  • Melanoma-specific survival (MSS) and progression-free survival (PFS) were calculated using Kaplan-Meier and log-rank tests.

    • Main Results:

    • First-line liver-directed therapy demonstrated significantly longer median MSS (28 months) compared to first-line systemic therapy (10 months).
    • Patients diagnosed with metastases between 2016-2021, receiving first-line liver-directed therapy, showed the best survival outcomes.
    • The study focused on liver metastases, as they represent the primary metastatic site in over 90% of cases.

    Conclusions:

    • Melanoma-specific survival for uveal melanoma has significantly improved in recent years.
    • First-line liver-directed therapy is associated with superior survival compared to first-line systemic therapy.
    • Future research should explore combinations of novel systemic therapies (e.g., immune checkpoint inhibitors, tebentafusp) with liver-specific treatments.